Caribou Biosciences to Participate in Citi’s 16Th Annual BioPharma Virtual Conference

Rhea-AI Summary

Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, Ph.D., will join a panel at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, at 10:40 am ET. The panel, titled “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” will focus on advances in cell therapies. A live and archived webcast will be available for 30 days on the company’s website. Caribou is committed to developing next-generation, genome-edited cell therapies using its proprietary technology.

BERKELEY, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a panel discussion entitled “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy” on Thursday, September 9, 2021 at 10:40 am ET. The panel is being hosted at Citi’s 16^Th Annual BioPharma Virtual Conference.

A live and archived webcast of the discussion will be accessible on the Events page of the Investors section on Caribou’s website at www.cariboubio.com for 30 days following the event.

About Caribou Biosciences, Inc.
Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company’s proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences, Inc. Media Contact:	Caribou Biosciences, Inc. Investor Relations Contact:
Greg Kelley	Elizabeth Wolffe, Ph.D. and Sylvia Wheeler
Ogilvy	Wheelhouse LSA
gregory.kelley@ogilvy.com	lwolffe@wheelhouselsa.com
617-461-4023	swheeler@wheelhouselsa.com

FAQ

What event will Caribou Biosciences participate in on September 9, 2021?

Caribou Biosciences will participate in Citi’s 16th Annual BioPharma Virtual Conference.

What is the focus of the panel discussion Caribou's CEO will join?

The panel discussion, titled 'Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,' will focus on advancements in cell therapies.

How can I access the Caribou Biosciences panel discussion?

The panel discussion will be accessible via a live and archived webcast on Caribou's website for 30 days following the event.

What is Caribou Biosciences' main focus?

Caribou Biosciences focuses on developing next-generation, genome-edited cell therapies for serious diseases using its proprietary chRDNA technology.

Who is presenting at the event on behalf of Caribou Biosciences?

Rachel Haurwitz, Ph.D., the president and CEO of Caribou Biosciences, will be presenting at the event.